Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
NYSE: BHVN · IEX Real-Time Price · USD
38.97
+0.43 (1.12%)
At close: Apr 26, 2024, 4:00 PM
38.72
-0.25 (-0.64%)
After-hours: Apr 26, 2024, 7:54 PM EDT
BHVN Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for BHVN stock have an average target of 51.63, with a low estimate of 24 and a high estimate of 63. The average target predicts an increase of 32.49% from the current stock price of 38.97.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BHVN stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 3 | 3 | 3 |
| Buy | 4 | 5 | 5 | 5 | 6 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 7 | 7 | 8 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $59 → $60 | Strong Buy | Maintains | $59 → $60 | +53.96% | Apr 23, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 18, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 10, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $61 | Buy | Reiterates | $61 | +56.53% | Apr 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $63 | Strong Buy | Maintains | $50 → $63 | +61.66% | Mar 4, 2024 |
Financial Forecast
Revenue This Year
41.19M
Revenue Next Year
11.33M
from 41.19M
Decreased by -72.48%
EPS This Year
-3.70
from -5.73
EPS Next Year
-6.34
from -3.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.0M | 52.5M | 458.9M | 562.9M | 833.8M |
| Avg | 11.3M | 16.3M | 163.3M | 391.3M | 615.2M |
| Low | n/a | n/a | n/a | 186.2M | 367.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 363.2% | 2,712.6% | 244.7% | 113.1% |
| Avg | - | 44.0% | 901.0% | 139.6% | 57.2% |
| Low | - | - | - | 14.0% | -6.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -4.12 | -3.47 | -3.89 |
| Avg | -6.34 | -3.37 | -4.98 |
| Low | -7.80 | -3.23 | -6.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.